4//SEC Filing
Bazemore Todd 4
Accession 0001415889-23-009134
CIK 0001479419other
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 8:00 PM ET
Size
26.8 KB
Accession
0001415889-23-009134
Insider Transaction Report
Form 4
Bazemore Todd
SEE REMARKS
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2023-05-31−3,499→ 0 totalExercise: $259.50Exp: 2029-01-01→ Common Stock (3,499 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−499→ 0 totalExercise: $643.00Exp: 2028-02-06→ Common Stock (499 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−864→ 0 totalExercise: $68.50Exp: 2032-01-03→ Common Stock (864 underlying) - Award
Common Stock
2023-05-31+21,158→ 35,993 total - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−3,439→ 0 totalExercise: $980.00Exp: 2027-11-19→ Common Stock (3,439 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−2,400→ 0 totalExercise: $192.00Exp: 2030-01-01→ Common Stock (2,400 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−3,499→ 0 totalExercise: $172.50Exp: 2029-10-10→ Common Stock (3,499 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−2,199→ 0 totalExercise: $343.00Exp: 2031-01-03→ Common Stock (2,199 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−4,759→ 0 totalExercise: $68.50Exp: 2032-01-03→ Common Stock (4,759 underlying)
Holdings
- 1(indirect: By son)
Common Stock
Footnotes (11)
- [F1]On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 16,011 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 5,147 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.
- [F10]The canceled option was granted on January 3, 2022 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F11]The canceled option was granted on January 3, 2022 and provided for the purchase of up to 2,160 shares of common stock of the issuer based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters, of which, prior to the option exchange program, options to purchase 576 shares had vested, options to purchase 1,152 shares had been forfeited and options to purchase up to 432 shares were unvested assuming maximum level of achievement (options to purchase 288 shares were unvested assuming target level of achievement). The vested portion of the option and the unvested portion of the option assuming target level of achievement were eligible for the issuer's option exchange program.
- [F2]Includes 34,142 unvested RSUs.
- [F3]The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.
- [F4]The canceled option was granted on November 20, 2017 and provided for vesting over four years with 25% of the shares underlying the option vested on November 20, 2018 and an additional 1/48th of the shares underlying the option vested at the end of each successive one-month period thereafter.
- [F5]The canceled option was granted on February 7, 2018 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F6]The canceled option was granted on January 2, 2019 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F7]The canceled option was granted on October 11, 2019 and provided for vesting with respect to 1/48th of the shares underlying the option on November 15, 2019 and 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F8]The canceled option was granted on January 2, 2020 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F9]The canceled option was granted on January 4, 2021 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
Documents
Issuer
Kala Pharmaceuticals, Inc.
CIK 0001479419
Entity typeother
Related Parties
1- filerCIK 0001605767
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 8:00 PM ET
- Size
- 26.8 KB